Private Advisor Group LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,328 shares of the pharmaceutical company’s stock after buying an additional 94 shares during the period. Private Advisor Group LLC’s holdings in Vertex Pharmaceuticals were worth $607,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,483,388 shares of the pharmaceutical company’s stock worth $2,047,986,000 after buying an additional 235,525 shares during the last quarter. Capital World Investors increased its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock worth $1,944,119,000 after buying an additional 599,586 shares during the last quarter. State Street Corp increased its position in shares of Vertex Pharmaceuticals by 2.7% in the fourth quarter. State Street Corp now owns 11,774,161 shares of the pharmaceutical company’s stock worth $867,393,000 after buying an additional 308,574 shares during the last quarter. Orbimed Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 34.0% in the fourth quarter. Orbimed Advisors LLC now owns 2,159,400 shares of the pharmaceutical company’s stock worth $159,083,000 after buying an additional 547,400 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Vertex Pharmaceuticals by 0.3% in the first quarter. Bank of New York Mellon Corp now owns 2,084,233 shares of the pharmaceutical company’s stock worth $227,910,000 after buying an additional 5,611 shares during the last quarter. 94.38% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.73% during midday trading on Friday, hitting $123.14. 3,152,299 shares of the company were exchanged. The company has a market capitalization of $30.67 billion, a P/E ratio of 171.74 and a beta of 1.65. The company has a 50-day moving average of $120.30 and a 200 day moving average of $97.79. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $130.69.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.09. The business had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. Vertex Pharmaceuticals’s revenue for the quarter was up 79.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.09 earnings per share. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post $1.66 earnings per share for the current fiscal year.

WARNING: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/06/16/vertex-pharmaceuticals-incorporated-vrtx-position-raised-by-private-advisor-group-llc-updated-updated.html.

VRTX has been the topic of a number of research analyst reports. Vetr raised shares of Vertex Pharmaceuticals from a “sell” rating to a “buy” rating and set a $102.50 price objective on the stock in a research report on Tuesday, March 14th. Robert W. Baird reaffirmed an “outperform” rating and set a $115.00 price objective on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 29th. BMO Capital Markets raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $89.67 to $100.00 in a research report on Wednesday, March 29th. Jefferies Group LLC reissued a “buy” rating and issued a $126.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, June 9th. Finally, Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. Nine analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $117.02.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 147,101 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $129.50, for a total transaction of $19,049,579.50. Following the completion of the transaction, the chief executive officer now owns 312,142 shares of the company’s stock, valued at $40,422,389. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 7,500 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $130.00, for a total value of $975,000.00. Following the transaction, the executive vice president now directly owns 113,511 shares of the company’s stock, valued at approximately $14,756,430. The disclosure for this sale can be found here. In the last ninety days, insiders sold 499,175 shares of company stock valued at $60,610,079. 1.90% of the stock is owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.